Atara Biotherapeutics Inc (ATRA)

Atara Biotherapeutics' stock has experienced volatility, including a 57% drop on January 12, 2026, after the FDA issued a second CRL for tabelecleucel. A class action lawsuit was filed on behalf of investors alleging the company misled them. Shares surged by 64% on March 16, 2026, following the announcement of its Q4 and full-year 2025 financial results, but these gains moderated. Overall, the share price declined by 22.73% between March 31, 2025, and March 27, 2026, with high volatility over the past three months.

Information regarding demand seasonality for Atara Biotherapeutics' products is not explicitly available. Demand for its products is primarily driven by medical need and physician prescriptions rather than traditional consumer seasonality. The company is in the early stages of commercialization, making traditional demand seasonality less applicable.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing allogeneic T-cell immunotherapies for serious diseases. The company uses its EBV T-cell platform to develop therapies such as Tab-cel (Ebvallo), ATA3431, ATA3219, and ATA188. Tab-cel is in Phase 3 clinical trials for EBV-driven PTLD and nasopharyngeal carcinoma. ATA3219 is an allogeneic CAR T immunotherapy targeting CD19 for B-cell malignancies and autoimmune diseases, while ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for similar conditions.

Atara Biotherapeutics operates in the United States and the United Kingdom, with its headquarters in Thousand Oaks, California. Ebvallo is approved for sale within the 27 European Union member countries since late 2022.

Atara Biotherapeutics' brand reputation has been negatively impacted by the FDA's second rejection of tabelecleucel in January 2026, citing deficiencies in the ALLELE study. A class-action lawsuit alleging investor deception further damaged its reputation. The company has faced financial losses, cash burn, shareholder dilution, and a failure to generate meaningful product revenue in the U.S. over the past five years, contributing to a negative perception.

Atara Biotherapeutics has a significant portion of its shares held by institutional and insider owners. Institutional shareholders hold 28.43% of the company's stock, while insider ownership stands at 50.62%. Major institutional owners include EcoR1 Capital, LLC, Redmile Group, LLC, Vanguard Group Inc, Globeflex Capital L P, BlackRock, Inc., Geode Capital Management, Llc, Mackenzie Financial Corp, Acadian Asset Management Llc, Staley Capital Advisers Inc, Bridgeway Capital Management Inc, Point72 Asset Management, L.P., Federated Hermes, Inc., Connor, Clark & Lunn Investment Management Ltd., Cambridge Investment Research Advisors, Inc., SBI Securities Co., Ltd., and Vanguard Fiduciary Trust Co.. Prominent individual or insider owners include Domain Partners VIII LP, Panacea Innovation Ltd, and Adiumentum Capital Fund I LP, with Domain Partners VIII LP being the largest individual shareholder, owning 2.14 million shares representing 29.70% of the company.